middle.news

Invion Advances Cancer Trials with Key Milestones and New Funding

6:20pm on Sunday 1st of June, 2025 AEST Life Sciences
Read Story

Invion Advances Cancer Trials with Key Milestones and New Funding

6:20pm on Sunday 1st of June, 2025 AEST
Key Points
  • First patient dosed in Phase I/II non-melanoma skin cancer trial
  • Promising safety and efficacy signals from Phase II prostate cancer trial
  • Strategic partnerships advancing in South Korea with Hanlim Pharm and Dr.inB
  • Appointment of Prof Rob Ramsay as Scientific Advisor
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Invion (ASX:IVX)
OPEN ARTICLE